<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0002527'>Falls</z:hpo> are common in patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) </plain></SENT>
<SENT sid="1" pm="."><plain>Identification of the potential risk factors and developing preventive strategies for <z:hpo ids='HP_0002527'>falls</z:hpo> will have a significant impact in maintaining the quality of life in AD </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS: Clinical follow-up of 124 (74.1+/-6.1 years, range 62-88) mild to moderate AD patients in an outpatient memory clinic </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Postural sway, cognitive function, use of <z:chebi fb="25" ids="35476">neuroleptics</z:chebi>, severity of periventricular and deep white matter lesions, and the presence or absence of silent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarctions</z:e> on magnetic resonance imaging were assessed at baseline </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A total of 104 patients (84%) completed the study </plain></SENT>
<SENT sid="5" pm="."><plain>Fall events were confirmed in 42.3% (44/104) </plain></SENT>
<SENT sid="6" pm="."><plain>After adjustment for age, gender, and cognitive status, a high grade of periventricular white matter lesions (odds ratio 8.7 [95%CI 1.5 to 51.8], p = 0.017) and <z:chebi fb="25" ids="35476">neuroleptic</z:chebi> drug use (odds ratio 3.5 [95%CI 1.2 to 10.5], p = 0.027) were significantly associated with an increased risk of <z:hpo ids='HP_0002527'>falls</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Our results suggest that periventricular white matter lesions and the use of <z:chebi fb="25" ids="35476">neuroleptics</z:chebi> may be related to <z:hpo ids='HP_0002527'>falls</z:hpo> in mild to moderate AD </plain></SENT>
<SENT sid="8" pm="."><plain>A comprehensive risk management of <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> as well as the use of the smallest efficacious dose of <z:chebi fb="25" ids="35476">neuroleptics</z:chebi> in the treatment of behavioral and <z:e sem="disease" ids="C0852553" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychiatric symptoms</z:e> of AD should be recommended to help reduce the risk of unexpected <z:hpo ids='HP_0002527'>falls</z:hpo> </plain></SENT>
</text></document>